- Home
- CANF vs BBIO Comparison
CANF vs BBIO Comparison
Compare CANF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- BBIO
- Stock Information
- Founded
- CANF 1994
- BBIO 2015
- Country
- CANF Israel
- BBIO United States
- Employees
- CANF N/A
- BBIO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- BBIO Health Care
- Exchange
- CANF Nasdaq
- BBIO Nasdaq
- Market Cap
- CANF 7.9M
- BBIO N/A
- IPO Year
- CANF N/A
- BBIO 2019
- Fundamental
- Price
- CANF $1.20
- BBIO $33.87
- Analyst Decision
- CANF Strong Buy
- BBIO Strong Buy
- Analyst Count
- CANF 2
- BBIO 12
- Target Price
- CANF $14.00
- BBIO $53.00
- AVG Volume (30 Days)
- CANF 413.8K
- BBIO 2.8M
- Earning Date
- CANF 04-29-2025
- BBIO 05-01-2025
- Dividend Yield
- CANF N/A
- BBIO N/A
- EPS Growth
- CANF N/A
- BBIO N/A
- EPS
- CANF N/A
- BBIO N/A
- Revenue
- CANF $674,000.00
- BBIO $221,902,000.00
- Revenue This Year
- CANF $461.72
- BBIO $14.88
- Revenue Next Year
- CANF N/A
- BBIO $121.23
- P/E Ratio
- CANF N/A
- BBIO N/A
- Revenue Growth
- CANF N/A
- BBIO 2285.27
- 52 Week Low
- CANF $1.22
- BBIO $21.62
- 52 Week High
- CANF $4.69
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- BBIO 51.06
- Support Level
- CANF $1.22
- BBIO $33.10
- Resistance Level
- CANF $1.82
- BBIO $35.16
- Average True Range (ATR)
- CANF 0.13
- BBIO 2.25
- MACD
- CANF -0.02
- BBIO 0.09
- Stochastic Oscillator
- CANF 3.13
- BBIO 78.71
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).